S&P 500   4,067.76 (-0.30%)
DOW   34,245.41 (-1.00%)
QQQ   291.73 (-0.56%)
AAPL   147.10 (-0.63%)
MSFT   251.66 (-1.36%)
META   119.22 (+0.95%)
GOOGL   100.74 (-0.25%)
AMZN   95.29 (-1.29%)
TSLA   193.61 (-0.56%)
NVDA   168.22 (-0.60%)
NIO   12.06 (-5.63%)
BABA   86.27 (-1.47%)
AMD   76.89 (-0.95%)
T   19.24 (-0.21%)
MU   55.54 (-3.66%)
CGC   3.61 (-0.28%)
F   14.13 (+1.65%)
GE   85.08 (-1.04%)
DIS   96.98 (-0.91%)
AMC   7.44 (+2.90%)
PYPL   78.49 (+0.10%)
PFE   50.66 (+1.06%)
NFLX   316.06 (+3.45%)
S&P 500   4,067.76 (-0.30%)
DOW   34,245.41 (-1.00%)
QQQ   291.73 (-0.56%)
AAPL   147.10 (-0.63%)
MSFT   251.66 (-1.36%)
META   119.22 (+0.95%)
GOOGL   100.74 (-0.25%)
AMZN   95.29 (-1.29%)
TSLA   193.61 (-0.56%)
NVDA   168.22 (-0.60%)
NIO   12.06 (-5.63%)
BABA   86.27 (-1.47%)
AMD   76.89 (-0.95%)
T   19.24 (-0.21%)
MU   55.54 (-3.66%)
CGC   3.61 (-0.28%)
F   14.13 (+1.65%)
GE   85.08 (-1.04%)
DIS   96.98 (-0.91%)
AMC   7.44 (+2.90%)
PYPL   78.49 (+0.10%)
PFE   50.66 (+1.06%)
NFLX   316.06 (+3.45%)
S&P 500   4,067.76 (-0.30%)
DOW   34,245.41 (-1.00%)
QQQ   291.73 (-0.56%)
AAPL   147.10 (-0.63%)
MSFT   251.66 (-1.36%)
META   119.22 (+0.95%)
GOOGL   100.74 (-0.25%)
AMZN   95.29 (-1.29%)
TSLA   193.61 (-0.56%)
NVDA   168.22 (-0.60%)
NIO   12.06 (-5.63%)
BABA   86.27 (-1.47%)
AMD   76.89 (-0.95%)
T   19.24 (-0.21%)
MU   55.54 (-3.66%)
CGC   3.61 (-0.28%)
F   14.13 (+1.65%)
GE   85.08 (-1.04%)
DIS   96.98 (-0.91%)
AMC   7.44 (+2.90%)
PYPL   78.49 (+0.10%)
PFE   50.66 (+1.06%)
NFLX   316.06 (+3.45%)
S&P 500   4,067.76 (-0.30%)
DOW   34,245.41 (-1.00%)
QQQ   291.73 (-0.56%)
AAPL   147.10 (-0.63%)
MSFT   251.66 (-1.36%)
META   119.22 (+0.95%)
GOOGL   100.74 (-0.25%)
AMZN   95.29 (-1.29%)
TSLA   193.61 (-0.56%)
NVDA   168.22 (-0.60%)
NIO   12.06 (-5.63%)
BABA   86.27 (-1.47%)
AMD   76.89 (-0.95%)
T   19.24 (-0.21%)
MU   55.54 (-3.66%)
CGC   3.61 (-0.28%)
F   14.13 (+1.65%)
GE   85.08 (-1.04%)
DIS   96.98 (-0.91%)
AMC   7.44 (+2.90%)
PYPL   78.49 (+0.10%)
PFE   50.66 (+1.06%)
NFLX   316.06 (+3.45%)
NASDAQ:LPCN

Lipocine - LPCN Stock Forecast, Price & News

$0.45
+0.00 (+0.04%)
(As of 12/1/2022 10:11 AM ET)
Add
Compare
Today's Range
$0.45
$0.46
50-Day Range
$0.37
$0.51
52-Week Range
$0.36
$1.89
Volume
900 shs
Average Volume
160,845 shs
Market Capitalization
$39.86 million
P/E Ratio
11.26
Dividend Yield
N/A
Price Target
$4.00

Lipocine MarketRank™ Forecast

Analyst Rating
N/A
0.00 Rating Score
Upside/​Downside
788.3% Upside
$4.00 Price Target
Short Interest
Healthy
1.81% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.58mentions of Lipocine in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$51,217 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.13) to ($0.09) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.82 out of 5 stars

Medical Sector

835th out of 1,047 stocks

Pharmaceutical Preparations Industry

406th out of 512 stocks

LPCN stock logo

About Lipocine (NASDAQ:LPCN) Stock

Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis; LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis; LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression; LPCN 2101 for women with epilepsy, which has completed pre-clinical study; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.

Receive LPCN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lipocine and its competitors with MarketBeat's FREE daily newsletter.

LPCN Stock News Headlines

Lipocine (NASDAQ:LPCN) Now Covered by StockNews.com
LPCN: TLANDO Launched
Lipocine: Q2 Earnings Snapshot
Recap: Lipocine Q2 Earnings - Benzinga
Form 8-K Lipocine Inc. For: Aug 08 - StreetInsider.com
See More Headlines
Receive LPCN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lipocine and its competitors with MarketBeat's FREE daily newsletter.

LPCN Company Calendar

Last Earnings
11/10/2021
Today
12/01/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/08/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LPCN
Employees
13
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.00
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+788.3%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$-630,000.00
Pretax Margin
24.69%

Debt

Sales & Book Value

Annual Sales
$16.14 million
Cash Flow
$0.05 per share
Book Value
$0.43 per share

Miscellaneous

Free Float
83,908,000
Market Cap
$39.86 million
Optionable
Optionable
Beta
0.55

Key Executives

  • Dr. Mahesh V. Patel Ph.D. (Age 65)
    Co-Founder, Interim Principal Financial Officer, Chairman, Pres & CEO
    Comp: $681.52k
  • Mr. Morgan R. Brown CPA (Age 54)
    CPA, M.B.A., MBA, Corp. Sec.
    Comp: $472.45k
  • Mr. Nachiappan Chidambaram Ph.D. (Age 53)
    VP of Product Devel.
    Comp: $323.22k
  • Mr. Logan Morse (Age 52)
    VP of Sales, Marketing & Operations
  • Ms. Krista Fogarty (Age 54)
    Principal Accounting Officer & Corp. Controller
  • Dr. Anthony DelConte M.D. (Age 64)
    M. D., Chief Medical Director
  • Dr. George G. Nomikos M.D.
    Ph.D., Chief Medical Officer













LPCN Stock - Frequently Asked Questions

What is Lipocine's stock price forecast for 2023?

0 analysts have issued twelve-month price targets for Lipocine's shares. Their LPCN share price forecasts range from $4.00 to $4.00. On average, they anticipate the company's stock price to reach $4.00 in the next year. This suggests a possible upside of 788.7% from the stock's current price.
View analysts price targets for LPCN
or view top-rated stocks among Wall Street analysts.

How have LPCN shares performed in 2022?

Lipocine's stock was trading at $0.9911 at the beginning of the year. Since then, LPCN stock has decreased by 54.6% and is now trading at $0.4501.
View the best growth stocks for 2022 here
.

When is Lipocine's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 8th 2023.
View our LPCN earnings forecast
.

How were Lipocine's earnings last quarter?

Lipocine Inc. (NASDAQ:LPCN) released its quarterly earnings data on Wednesday, November, 10th. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.01. The specialty pharmaceutical company had revenue of $0.06 million for the quarter.

What other stocks do shareholders of Lipocine own?
What is Lipocine's stock symbol?

Lipocine trades on the NASDAQ under the ticker symbol "LPCN."

Who are Lipocine's major shareholders?

Lipocine's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (1.64%), Two Sigma Investments LP (0.37%), Two Sigma Advisers LP (0.24%), Renaissance Technologies LLC (0.23%), Mercer Global Advisors Inc. ADV (0.18%) and Virtu Financial LLC (0.11%). Insiders that own company stock include John W Higuchi, Krista Fogarty, Mahesh V Patel, Morgan R Brown and Spyros Papapetropoulos.
View institutional ownership trends
.

How do I buy shares of Lipocine?

Shares of LPCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lipocine's stock price today?

One share of LPCN stock can currently be purchased for approximately $0.45.

How much money does Lipocine make?

Lipocine (NASDAQ:LPCN) has a market capitalization of $39.84 million and generates $16.14 million in revenue each year. The specialty pharmaceutical company earns $-630,000.00 in net income (profit) each year or $0.04 on an earnings per share basis.

How can I contact Lipocine?

Lipocine's mailing address is 675 ARAPEEN DRIVE SUITE 202, SALT LAKE CITY X1, 84108. The official website for the company is www.lipocine.com. The specialty pharmaceutical company can be reached via phone at (801) 994-7383, via email at john.woolford@westwicke.co, or via fax at 801-994-7388.

This page (NASDAQ:LPCN) was last updated on 12/1/2022 by MarketBeat.com Staff